Vertigo3d There is quite a pronounced valuation gap in the pharmaceuticals sector, with richly priced names like Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) on the high-end of the spectrum, and others like Bristol Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD) on the other end. This brings me to the even lower-priced name, Viatris Inc. (NASDAQ:VTRS) which falls in the deep value category. I last covered VTRS back in June of last year, noting that it wouldn't take much to move the nee ...